Genetic variation within TLR10 is associated with Crohn's disease in a New Zealand population

Human Immunology

Volumn 73, Issue 4, 2012, Pages 416-420

  Morgan, Angharad R ^a,b   Lam, Wen Jiun ^a,b   Han, Dug Yeo ^a,b   Fraser, Alan G ^a,b   Ferguson, Lynnette R ^a,b  

^a THE UNIVERSITY OF AUCKLAND   (New Zealand)

^b Nutrigenomics New Zealand   (New Zealand)

Author keywords

Crohn's disease; Genetic association; TLR10

Indexed keywords

TOLL LIKE RECEPTOR 10;

ADOLESCENT; ADULT; AGE; ARTICLE; CASE CONTROL STUDY; COLON CROHN DISEASE; CONTROLLED STUDY; CROHN DISEASE; DISEASE PREDISPOSITION; FEMALE; GENETIC ASSOCIATION; GENETIC VARIABILITY; HAPLOTYPE; HUMAN; INFLAMMATORY DISEASE; INTESTINE RESECTION; MAJOR CLINICAL STUDY; MALE; NEW ZEALAND; OUTCOME ASSESSMENT; PHENOTYPE; PREVALENCE; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM;

ADOLESCENT; ADULT; CASE-CONTROL STUDIES; CHILD; CROHN DISEASE; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; NEW ZEALAND; PHENOTYPE; POLYMORPHISM, SINGLE NUCLEOTIDE; TOLL-LIKE RECEPTOR 10; YOUNG ADULT;

EID: 84859108570     PISSN: 01988859     EISSN: 18791166     Source Type: Journal    
DOI: 10.1016/j.humimm.2012.01.015     Document Type: Article

References (24)

1. O'Neill L.A. The interleukin-1 receptor/Toll-like receptor superfamily: 10 Years of progress. Immunol Rev 2008, 226:10-18.
2. Lemaitre B., Nicolas E., Michaut L., Reichhart J.M., Hoffmann J.A. The dorsoventral regulatory gene cassette spatzle/Toll/cactus controls the potent antifungal response in Drosophila adults. Cell 1996, 86:973-983.
3. Oda K., Kitano H. A comprehensive map of the Toll-like receptor signaling network. Mol Syst Biol 2006, 2:0015.
4. Cole J.E., Georgiou E., Monaco C. The expression and functions of toll-like receptors in atherosclerosis. Mediators of Inflamm 2010, 2010:393946.
5. Brand S., Staudinger T., Schnitzler F., Pfennig S., Hofbauer K., Dambacher J., et al. The role of Toll-like receptor 4 Asp299Gly and Thr399Ile polymorphisms and CARD15/NOD2 mutations in the susceptibility and phenotype of Crohn's disease. Inflamm Bowel Dis 2005, 11:645-652.
6. Török H.P., Glas J., Tonenchi L., Bruennler G., Folwaczny M., Folwaczny C. Crohn's disease is associated with a toll-like receptor-9 polymorphism. Gastroenterology 2004, 127:365-366.
7. Török H.P., Glas J., Endres I., Tonenchi L., Teshome M.Y., Wetzke M., et al. Epistasis between toll-like receptor-9 polymorphisms and variants in NOD2 and IL23R modulates susceptibility to Crohn's disease. Am J Gastroenterol 2009, 104:1723-1733.
8. Abad C., González-Escribano M.F., Diaz-Gallo L.M., Lucena-Soto J.M., Márquez J.L., Leo E., et al. Association of Toll-like receptor 10 and susceptibility to Crohn's disease independent of NOD2. Genes Immun 2011, 12:635-642.
9. Gearry R.B., Richardson A., Frampton C.M., Collett J.A., Burt M.J., Chapman B.A., et al. High incidenceof Crohn's disease in Canterbury, New Zealand: Results of an epidemiologic study. Inflamm Bowel Dis 2006, 12:936-943.
10. Yap J., Wesley A., Mouat S., et al. Paediatric inflammatory bowel disease in New Zealand. N Z Med J 2008, 121:19-34.
11. Tarrant K.M., Barclay M.L., Frampton C.M., Gearry R.B. Perianal disease predicts changes in Crohn's disease phenotype-results of a population-based study of inflammatory bowel disease phenotype. Am J Gastroenterol 2008, 103:3082-3093.
12. Lennard-Jones J.E. Classification of inflammatory bowel disease. Scand J Gastroenterol 1989, 170:2-6.
13. Jurinke C., van der Boom D., Cantor C.R., Köster H. The use of massARRAY technology for high throughput genotyping. Adv Biochem Eng/Biotechnol 2002, 77:57-74.
14. Storm N., Darnhofer-Patel B., van der Boom D., Rodi C.P. MALDI-TOF mass spectrometry-based SNP genotyping. Methods Mol Biol 2003, 212:241-262.
15. Barrett J.C., Fry B., Maller J., Daly M.J. Haploview: Analysis and visualization of LD and haplotype maps. Bioinformatics 2005, 21:263-265.
16. Gabriel S.B., Schaffner S.F., Nguyen H., Moore J.M., Roy J., Blumenstiel B., et al. The structure of haplotype blocks in the human genome. Science 2002, 296:2225-2229.
17. Bender R., Lange S. Adjusting for multiple testing-when and how?. J Clin Epidemiol 2001, 54:343-349.
18. Jones H.E., Ohlssen D.I., Spiegelhalter D.J. Use of the false discovery rate when comparing multiple health care providers. J Clin Epidemiol 2008, 61:232-240.
19. Kormann M.S., Depner M., Hartl D., Klopp N., Illig T., Adamski J., et al. Toll-like receptor heterodimer variants protect from childhood asthma. J Allergy Clin Immunol 2008, 122:86-92.
20. Lazarus R., Raby B.A., Lange C., Silverman E.K., Kwiatkowski D.J., Vercelli D., et al. Toll-like receptor 10 genetic variation is associated with asthma in two independent samples. Am J Respir Crit Care Med 2004, 170:594-600.
21. Mailaparambil B., Krueger M., Heinze J., Forster J., Heinzmann A. Polymorphisms of toll like receptors in the genetics of severe RSV associated diseases. Dis Markers 2008, 25:59-65.
22. Zhou X.X., Jia W.H., Shen G.P., Qin H.D., Yu X.J., Chen L.Z., et al. Sequence variants in Toll-like receptor 10 are associated with nasopharyngeal carcinoma risk. Cancer Epidemiol Biomarkers Prev 2006, 15:862-866.
23. Rose J.D.R., Roberts G.M., Williams G., Mayberry J.F., Rhodes J. Cardiff Crohn's jubilee. The incidence over 50 years. Gut 1988, 29:346-351.
24. Polito J.M., Childs B., Mellits E.D., Tokayer A.Z., Harris M.L., Bayless T.M. Crohn's disease: Influence of age at diagnosis on site and clinical type of disease. Gastroenterology 1996, 111:580-586.